Ketoconazole and the modulation of multidrug resistance-mediated transport in Caco-2 and MDCKII-MDR1 drug transport models

References

• Anderle P, Rakhmanova V, Woodford K, Zerangue N, Sadée W. Messenger RNA expression of transporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared with human intestines. Pharmaceutical Research 2003; 20: 3–15
   PubMedGoogle Scholar
• Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Advanced Drug Delivery 2001; 46: 27–43
   PubMed Web of Science ®Google Scholar
• Augustijns PF. Uptake and transport characteristics of chloroquine in an in-vitro cell culture system of the intestinal mucosa, Caco-2. Journal of Pharmacy Pharmacology 1996; 48: 277–280
   PubMedGoogle Scholar
• Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31: 469–497
   PubMed Web of Science ®Google Scholar
• Balimane PV, Han YH, Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS Journal 2006; 8: E1–E13
   PubMed Web of Science ®Google Scholar
• Baxter JG, Brass C, Schentag JJ, Slaughter RL. Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. Journal Pharmaceutical Sciences 1986; 75: 443–447
   PubMedGoogle Scholar
• Behrens I, Kamm W, Dantzig AH, Kissel T. Variation of peptide transporter (PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin. Journal of Pharmaceutical Sciences 2004; 93: 1743–1754
   PubMed Web of Science ®Google Scholar
• Bois F, Beney C, Boumendjel A, Mariotte A-M, Conseil G, Di Pietro A. Halogenated chalcones with high-affinity binding to P-glycoprotein: Potential modulators of multidrug resistance. Journal of Medicinal Chemistry 1998; 41: 4161–4164
   PubMed Web of Science ®Google Scholar
• Chow H-HS, Cai Y, Alberts DS, Hakim I, Dorr RT, Shahi F, Crowell JA, Yang CS, Hara Y. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer, Epidemiology, Biomarkers and Prevention 2001; 10: 53–58
   PubMed Web of Science ®Google Scholar
• Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, Di Pietro A. Flavonoids: A class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Biochemistry 1998; 95: 9831–9836
   Google Scholar
• Crivori P, Reinach B, Pezzetta D, Poggesi I. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Molecular Pharmacology 2006; 3: 33–44
   PubMed Web of Science ®Google Scholar
• Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Parker G. Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. Journal of Antimicrobial Chemotherapy 1983; 12: 185–188
   PubMed Web of Science ®Google Scholar
• De Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochemical and Biophysical Research Communications 1992; 189: 551–557
   PubMed Web of Science ®Google Scholar
• Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clinical Pharmacology and Therapeutics 2002; 71: 11–20
   PubMed Web of Science ®Google Scholar
• Ebert B, Seidel A, Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 2005; 26: 1754–1763
   PubMed Web of Science ®Google Scholar
• Eneroth A, Astrom E, Hoogstraate J, Schrenk D, Conrad S, Kauffmann H-M, Gjellan K. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. European Journal of Pharmaceutical Sciences 2001; 12: 205–214
   PubMed Web of Science ®Google Scholar
• Essodaïgui M, Broxterman HJ, Garnier-Suillerot A. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry 1998; 37: 2243–2250
   PubMed Web of Science ®Google Scholar
• Evers R, Kool M, Smith AJ, Van Deemter L, De Hass M, Borst P. Inhibitory effect of the reversal agents, V-104, GF120918 and pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. British Journal of Cancer 2000; 83: 366–374
   PubMed Web of Science ®Google Scholar
• Evers R, Zaman GJR, Van Deemter L, Jansen H, Calafat J, Oomen LCJM, Elferink RPJO, Borst P, Schinkel AH. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. Journal of Clinical Investigation 1996; 97: 1211–1218
   PubMed Web of Science ®Google Scholar
• Feller N, Broxterman HJ, Wahrer DC, Pinedo HM. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): No inhibition by intracellular glutathione depletion. FEBS Letters 1995; 368: 385–388
   PubMed Web of Science ®Google Scholar
• Findor JA, Gorda JA, Igartija EB, Avagnina A. Ketoconazole-induced liver damaged. Medicina 1998; 58: 277–281
   PubMedGoogle Scholar
• First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW. Cyclosporine–ketoconazole interaction. Transplantation 1993; 55: 1000–1004
   PubMed Web of Science ®Google Scholar
• Gerhauser C, Alt A, Heiss E, Gamal-Eldeen A, Klimo K, Knauft J, Neumann I, Scherf H-R, Frank N, Bartsch H, et al. Cancer chemopreventive activity of xanthohumol, a natural product derived from Hop. Molecular Cancer Therapeutics 2002; 1: 959–969
   PubMed Web of Science ®Google Scholar
• Germann UA. P-glycoprotein — a mediator of multidrug resistance in tumour cells. European Journal of Cancer 1996; 32A: 927–944
   PubMed Web of Science ®Google Scholar
• Ghosal A, Satoh K, Thomas PE, Bush E, Moore D. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metabolism and Disposition 1996; 24: 940–947
   PubMed Web of Science ®Google Scholar
• Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Roland Wolf C, Friedberg T. Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochemical Pharmacology 2002; 64: 1569–1578
   PubMed Web of Science ®Google Scholar
• Grés M-C, Julian B, Bourrié M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y, Fabre G. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: Comparison with the parental Caco-2 cell line. Pharmaceutical Research 1998; 15: 726–733
   PubMed Web of Science ®Google Scholar
• Gutmann K, Fricker G, Torok M, Michael S, Beglinger C, Drewe J. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharmaceutical Research 1999; 16: 402–407
   PubMed Web of Science ®Google Scholar
• Hadjeri M, Barbier M, Ronot X, Mariotte AM, Boumendjel A, Boutonnat J. Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues. Journal of Medicinal Chemistry 2003; 46: 2125–2131
   PubMed Web of Science ®Google Scholar
• Heyerick A, Vervarcke S, Depypere H, Bracke M, Keukeleire D. A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardize hop extract to alleviate menopausal discomforts. Maturitas 2006; 54: 164–175
   PubMed Web of Science ®Google Scholar
• Hilgendorf C, Spahn-Langguth H, Regårdh CG, Lipka E, Amidon GL, Langguth P. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: Permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. Journal of Pharmaceutical Sciences 2000; 89: 63–75
   PubMed Web of Science ®Google Scholar
• Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants J. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrobial Agents and Chemotherapy 1986; 30: 206–210
   PubMed Web of Science ®Google Scholar
• Hunter J, Hirst BH. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Advance Drug Delivery Reviews 1997; 25: 129–157
   Web of Science ®Google Scholar
• Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Journal of Biological Chemistry 1993; 268: 14991–14997
   PubMed Web of Science ®Google Scholar
• Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochimica et Biophysica Acta 2002; 1542: 149–159
   PubMed Web of Science ®Google Scholar
• Jubelirer SJ, Hogan T. High dose ketoconazole for the treatment of hormone refractory metastatic prostate carcinoma: 16 cases and review of the literature. Journal of Urology 1989; 142: 89–91
   PubMedGoogle Scholar
• Kageyama M, Namiki H, Fukushima H, Ito Y, Shibata N, Takada K. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biological and Pharmaceutical Bulletin 2005; 28: 316–322
   PubMed Web of Science ®Google Scholar
• Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmaceutical Research 1999; 16: 408–414
   PubMed Web of Science ®Google Scholar
• Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. British Medical Journal 1987; 294: 419–422
   PubMed Web of Science ®Google Scholar
• Louvard D. Apical membrane aminopeptidase appears at site of cell–cell contact in cultured kidney epithelial cells. Proceedings of the National Academy of Sciences, USA 1980; 77: 4132–4136
   PubMed Web of Science ®Google Scholar
• Machavaram K, Gundu J, Yamsani M. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: A possible role of P-glycoprotein. Drug Metabolism Drug Interactions 2006; 22: 47–65
   PubMedGoogle Scholar
• Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proceedings of the National Academy Sciences, USA 2004; 101: 3569–3574
   PubMed Web of Science ®Google Scholar
• Miranda CL, Stevens JF, Helmrich A, Henderson MC, Rodriguez RJ, Yang Y-H, Deinzer ML, Barnes DW, Buhler DR. Antiproliferative and cytotoxic effects of prenylated flavonoids from Hops (Humulus luplus) in human cancer cell lines. Food and Chemical Toxicology 1999; 37: 271–285
   PubMed Web of Science ®Google Scholar
• Miranda CL, Stevens JF, Ivanov V, McCall M, Frei B, Deinzer ML, Buhler DR. Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones in vitro. Journal of Agricultural and Food Chemistry 2000a; 48: 3876–3884
   PubMed Web of Science ®Google Scholar
• Miranda CL, Yang Y-H, Henderson MC, Stevens JF, Santana-Rios G, Deinzer ML, Buhler DR. Prenylflavonoids from HOPS inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4,5-F]quinoline, mediated by cDNA-expressed human CYP1A2. Drug Metabolism and Disposition 2000b; 28: 1297–1302
   PubMed Web of Science ®Google Scholar
• Mizuma T, Momota R, Haga M, Hayashi M. Factors affecting glucuronidation activity in Caco-2 cells. Drug Metabolism and Pharmacokinetics 2004; 19: 130–134
   PubMedGoogle Scholar
• Moaddel R, Bullock P, Wainer I. Development and characterization of an open tubular column containing immobilized P-glycoprotein for rapid on-line screening for P-glycoprotein substrates. Journal of Chromatography B 2004; 799: 255–263
   PubMedGoogle Scholar
• Nagle D, Ferreira D, Zhou Y. Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives. Phytochemistry 2006; 67: 1849–1855
   PubMed Web of Science ®Google Scholar
• Ng KH, Lim BG, Wong KP. Sulfate conjugating and transport functions of MDCK distal tubular cells. Kidney International 2003; 63: 976–986
   PubMed Web of Science ®Google Scholar
• Nies AT, Cantz T, Brom M, Leier I, Keppler D. Expression of the apical conjugate export pump, Mrp2, in the polarized hepatoma cell line, WIF-B. Hepatology. 1998; 28: 1332–1340
   PubMed Web of Science ®Google Scholar
• Odocha O, Kelly B, Trimble S, Murigande C, Toussaint RM, Callender CO. Cost-containment strategies in transplantation: The utility of cyclosporine–ketoconazole combination therapy. Transplantation Proceedings 1996; 28: 907–909
   PubMed Web of Science ®Google Scholar
• Osypiw JC, Gleeson D, Lobley RW, Pemberton PW, McMahon RFT. Acid–base transport systems in a polarized human intestinal cell monolayer: Caco-2. Experimental Physiology 1994; 79: 723–739
   PubMedGoogle Scholar
• Pont A, Graybill JR, Craven PC, Galgiani JN, Dismukes WE, Reitz RE, Stevens DA. High-dose ketoconazole therapy and adrenal and testicular function in humans. Archives of Internal Medicine 1984; 144: 2150–2153
   PubMed Web of Science ®Google Scholar
• Ringel SM. New antifungal agents for the systemic mycoses. Mycopathologia 1990; 109: 77–87
   Google Scholar
• Rodriguez R, Acosta D. Inhibition of mitochondrial function in isolated rat liver mitochondria by azole antifungals. Journal of Biochemical Toxicology 1996; 11: 127–131
   PubMedGoogle Scholar
• Rodriguez-Proteau R, Mata JE, Miranda CL, Fan Y, Brown JJ, Buhler DR. Plant polyphenols and multidrug resistance: Effects of dietary flavonoids on drug transporters in Caco-2 and MDCKII-MDR1 cell transport models. Xenobiotica 2006; 36: 41–58
   PubMed Web of Science ®Google Scholar
• Saad A, DePestel D, Carver PL. Factors influencing the magnitude and clinical significance of drug interaction between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730–1744
   PubMed Web of Science ®Google Scholar
• Schinkel A, Wagenaar E, Van Deemter L, Mol C, Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. Journal of Clinical Investigation 1995; 96: 1698–1705
   PubMed Web of Science ®Google Scholar
• Seeram N, Henning S, Niu Y, Lee R, Scheuller H, Heber D. Catechin and caffeine content of green tea dietary supplements and correlation with antioxidant activity. Journal of Agricultural and Food Chemistry 2006; 54: 1599–1603
   PubMed Web of Science ®Google Scholar
• Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. Journal of Urology 1994; 151: 485–491
   PubMed Web of Science ®Google Scholar
• Stevens JF, Taylor A, Deinzer ML. Quantitative analysis of xanthohumol and related prenylflavonoids in hops and beer by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A 1999; 832: 97–107
   PubMed Web of Science ®Google Scholar
• Stricker BHC, Blok APR, Bronkhorst FB, Van Parys GE, Desmet VJ. Ketoconazole-associated hepatic injury a clinicopathological study of 55 cases. Journal of Hepatology 1986; 3: 399–406
   PubMed Web of Science ®Google Scholar
• Sun J, He Z-G, Cheng G, Wang S-J, Hao X-H, Zou M-J. Multidrug resistance P-glycoprotein: Crucial significance in drug disposition and interaction. Medical Science Monitor 2004; 10: RA5–RA14
   PubMed Web of Science ®Google Scholar
• Taipalensuu J, Tavelin S, Lazorova L, Svensson A-C, Artursson P. Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. European Journal of Pharmaceutical Sciences 2004; 21: 69–75
   PubMed Web of Science ®Google Scholar
• Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, Lundgren B, Artursson P. Correlation of gene expression of ten drug efflux proteins of the ATP-Binding Cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. Journal of Pharmacology and Experimental Therapeutics 2001; 299: 164–170
   PubMed Web of Science ®Google Scholar
• Takano M, Hasegawa R, Fukuda T, Yumoto R, Najai J, Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midazolam, and ketoconazole in Caco-2 cells. European Journal of Pharmacology 1998; 358: 289–294
   PubMed Web of Science ®Google Scholar
• Tang F, Horie K, Borchardt RT. Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa?. Pharmaceutical Research 2002; 19: 773–779
   PubMed Web of Science ®Google Scholar
• Taub ME, Podila L, Ely D, Almeida I. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: Influence of cell line and modulator concentration on P-gp activity. Drug Metabolism and Disposition 2005; 33: 1679–1687
   PubMed Web of Science ®Google Scholar
• Tchamo DN, Dijoux-Franca M-G, Mariotte A-M, Tsamo E, Daskiewicz JB, Bayet C, Barron D, Conseil G, Di Pietro A. Prenylated xanthones as potential P-glycoprotein modulators. Bioorganic Medicinal Chemistry Letters 2000; 10: 1343–1345
   PubMed Web of Science ®Google Scholar
• Thwaites DT, Hirst BH, Simmons NL. Substrate specificity of the di/tripeptide transporter in human intestinal epithelia (Caco-2): Identification of substrates that undergo H+-coupled absorption. British Journal of Pharmacology 1994; 113: 1050–1056
   PubMed Web of Science ®Google Scholar
• Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anti-Cancer Drugs 1996; 7: 568–578
   PubMed Web of Science ®Google Scholar
• Vaidyanathan JB, Walle T. Cellular uptake and efflux of the tea flavonoid (–)-epicatechin-3-gallate in the human intestinal cell line Caco-2. Journal of Pharmacology and Experimental Therapeutics 2003; 307: 745–752
   PubMed Web of Science ®Google Scholar
• Wang E-J, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrobial Agents and Chemotherapy 2002; 46: 160–165
   PubMed Web of Science ®Google Scholar
• Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, McSurdy-Freed JE, Proksch JW, Smith BR. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metabolism and Disposition 2004; 32: 172–177
   PubMed Web of Science ®Google Scholar
• Yang CS, Chen L, Lee M-J, Balentine DA, Kuo MC, Schantz SP. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer, Epidemiology, Biomarkers and Prevention 1998; 7: 351–354
   PubMed Web of Science ®Google Scholar
• Yao HM, Chiou WL. The complexity of intestinal absorption and exsorption of digoxin in rats. International Journal of Pharmaceutics 2006; 322: 79–86
   PubMedGoogle Scholar
• Yu H, Cook T, Sinko P. Evidence for diminished functional expression of intestinal transporters in Caco-2 cell monolayers at high passages. Pharmaceutical Research 1997; 14: 757–762
   PubMed Web of Science ®Google Scholar
• Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, Takano M. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. Journal of Pharmacology and Experimental Therapeutics 1999; 289: 149–155
   PubMed Web of Science ®Google Scholar
• Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metabolism Reviews 2004; 36: 57–104
   PubMed Web of Science ®Google Scholar